Latest Breaking News On - Committee for medicinal products human use - Page 4 : comparemela.com

Update On FDA Priority Review Of Dupixent® (Dupilumab) For The Treatment Of COPD Patients With Type 2 Inflammation

TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food a

Massachusetts
United-states
Paris
France-general
France
China
Japan
Regeneron-velocimmune
Georged-yancopoulos
Clinical-research-program
Us-department-of-justice
Euronext

SIFI S.p.A.: SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis

ACI SANT'ANTONIO, Italy, May 31, 2024 /PRNewswire/ SIFI announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive

United-arab-emirates
China
Mexico
Germany
Santantonio
Sicilia
Italy
Turkey
Romania
Spain
Liechtenstein
Iceland

SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis

SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Iceland
China
Spain
Italy
Santantonio
Sicilia
Mexico
Germany
Norway
United-arab-emirates
Liechtenstein
Turkey

Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month

(RTTNews) - The U.S. Food and Drug Administration has extended by three months the target action date of its priority review of the supplemental B.

China
European-union
Committee-for-medicinal-products-human-use
European-medicines-agency
Regeneron-pharmaceuticals-inc
Drug-administration
More-such-health-news
Biologics-license-application
Medicinal-products
Human-use

Pfizer : Receives Positive CHMP Opinion for its One-Time Gene Therapy for Adults with Hemophilia B

NEW YORK, May 31, 2024 - Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for fidanacogene.

Committee-for-medicinal-products-human-use
European-medicines-agency
Pfizer-inc
Medicinal-products
Human-use